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Abstract
Increasing numbers of adults, particularly college students, are misusing prescription
stimulants primarily for cognitive/academic enhancement, so it is critical to explore
whether empirical findings support neurocognitive benefits of prescription stimulants.
Previous meta-analytic studies have supported small benefits from prescription stimulants
for the cognitive domains of inhibitory control and memory; however, no meta-analytic
studies have examined the effects on processing speed or the potential impairment on
other domains of cognition, including planning, decision-making, and cognitive
perseveration. Therefore, the present study conducted a meta-analysis of the available
literature examining the effects of prescription stimulants on specific measures of
processing speed, planning, decision-making, and cognitive perseveration among healthy
adult populations. The meta-analysis results indicated a positive influence of prescription
stimulant medication on processing speed accuracy, with an overall mean effect size of g
= 0.282 (95% CI 0.077, 0.488; n = 345). Neither improvements nor impairments were
revealed for planning time, planning accuracy, advantageous decision-making, or
cognitive perseveration; however findings are limited by the small number of studies
examining these outcomes. Findings support that prescription stimulant medication may
indeed act as a neurocognitive enhancer for accuracy measures of processing speed
without impeding other areas of cognition. Considering that adults are already engaging
in illegal use of prescription stimulants for academic enhancement, as well as the
potential for stimulant misuse to have serious side effects, the establishment of public
policies informed by interdisciplinary research surrounding this issue, whether restrictive
or liberal, is of critical importance.

NEUROCOGNITIVE ENHANCEMENT OR IMPAIRMENT?

3

Keywords:
Cognition
Processing Speed
Cognitive Perseveration
Prescription Stimulants
Meta-analysis

Public Health Significance:
Misuse of prescription stimulants, which hold a high abuse potential, is a growing
problem among student and non-student adults for enhancement of academic functioning
and work productivity. By investigating the cognitive effects of prescription stimulants,
the present meta-analytic study informs potential interventions and policy development
surrounding prescription stimulant misuse and diversion.
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Introduction
The efficacy of prescription stimulant medications for the reduction of AttentionDeficit/Hyperactivity Disorder (ADHD) symptomatology among adults and children has
been well documented through clinical trials and meta-analyses (Faraone, 2012; Faraone
& Biederman, 2002; Faraone & Buitelaar, 2010; Faraone and Glatt, 2010). Prescription
stimulant misuse for cognitive enhancement, as opposed to ADHD symptom
management, is a growing problem among adults and college students with and without
ADHD (Benson, Flory, Humphreys, & Lee, 2015; Weyandt et al., 2013; Weyandt et al.,
2014). College students consistently report enhancing academics as their primary
motivation for misusing stimulant medication (Benson et al., 2015; Weyandt et al., 2009;
Weyandt et al., 2013), and adults with ADHD have indicated productivity as a motivation
for stimulant misuse (Novak, Kroutil, Williams, & Van Brunt 2007). Although the
widespread misuse of prescription stimulants for cognitive enhancement highlights the
need for public policy addressing this issue, a number of questions remain about how best
to approach such policy. Policy development requires in-depth understanding of a) the
ethical and legal implications associated with prescription stimulant misuse, b) the
cognitive behavioral effects of these medications in populations with and without ADHD,
c) the underlying pharmacological mechanisms of these effects, and d) potential genetic
and neurodevelopmental variation across cognitive and behavioral effects. Although it is
beyond the scope of the present study to answer all of these questions, by elucidating the
potential effects of prescription stimulant medications for particular domains of cognitive
enhancement, we hope to contribute to an interdisciplinary dialogue spanning behavioral,
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cognitive, and developmental psychology, as well as clinical neuroscience, behavior
genetics, and pharmacology in order to help inform public policy.
Two previous reviews have assessed the effect of prescription stimulants on
cognition in adults with and without ADHD, concluding that the effects of stimulant
medications on cognitive enhancement vary according to population and task (Advokat,
2010; Smith & Farah, 2011). These reviews, however, relied on studies that were
underpowered and varied in design, potentially impeding comparisons across studies.
Indeed, Smith and Farah (2011) stated that although larger clinical studies assessing the
cognitive effects of stimulants are warranted, such studies are unlikely to be funded given
“cognitive enhancement falls between the two stools of research funding” (i.e., diseaseoriented and pharmaceutical funders) (p. 736). In their meta-analysis examining
prescription stimulant efficacy for ADHD symptoms, Faraone, Biederman, Spencer, and
Aleardi (2006) reported that comparing effect sizes and results across prescription
stimulant studies without using statistical techniques to account for study differences
(e.g., meta-analysis) would result in biased conclusions. Therefore, a meta-analysis
examining the efficacy of prescription stimulant medications for cognitive enhancement
in adults, accounting for medication type, medication dose, participant demographics and
study design, would greatly contribute to the existing literature.
One meta-analytic study (Ilieva, Hook, & Farah, 2015) has explored the effects of
prescription stimulant medication on cognition among adults. Findings from this study
supported small but significant effects of methylphenidate and amphetamine on working
memory (g = 0.13), episodic memory (g = 0.20) and inhibitory control (g = 0.20), and
moderate effects on delayed memory (g = 0.45). The researchers speculated that larger
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effects may be found among other domains of cognition related to learning (e.g.,
processing speed). An additional question that has been raised in the literature (Advokat,
2010; Ilieva, Boland, & Farah, 2013; Smith & Farah, 2011; Weyandt et al., 2013;
Weyandt et al., 2014) queries that even if positive benefits are associated with
prescription stimulant use in some areas of cognition, could these stimulants also be
associated with impairments of other components of cognition such as planning,
decision-making and perseveration?
To date, no meta-analyses have been conducted concerning the effects of
prescription stimulant medication on processing speed accuracy, planning time and
accuracy, advantageous decision-making, or cognitive perseveration. Findings from such
a study will provide important implications for the use and misuse of prescription
stimulants as a “smart pill” (Smith & Farah, 2011, p. 717) for adults seeking to enhance
their cognitive functioning and college students hoping to improve their academic
outcomes. Therefore, the present meta-analytic study examined whether prescription
stimulants play a role in these specific behaviors of cognition among healthy adults.
These particular cognitive behaviors were selected because a) to date, no meta-analytic
studies have examined the effects of prescription stimulants on these cognitive behaviors;
b) these particular cognitive behaviors will proffer important implications for academic
enhancement; and c) a pilot search of the literature indicated these areas have been
adequately studied across neuropsychological research.
Previous research supports the potential for prescription stimulants to benefit
processing speed and impede cognitive flexibility; however, the potential for positive or
negative effects from stimulants on planning and decision-making remains less clear.
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Processing speed has been described to rely on cognitive processes that involve attention
and response speed (Lezak, Howieson, Bigler, & Tranel, 2012) and previous research has
supported prescription stimulant benefits to these areas (Riccio, Waldrop, Reynolds, &
Lowe, 2001; Schlösser et al., 2009). Further, an increase in error rates on tests of
cognitive flexibility and set-shifting has been found to associate with prescription
stimulants (Advokat, 2010; Dyme, Sahakian, Golinko, & Rabe, 1982; Rogers et al.,
1999). Studies examining the effects of prescription stimulants on tasks of decisionmaking and planning, however, have mainly reported null effects (Agay, Yechiam,
Carmel, & Levkovitz, 2010; Agay, Yechiam, Carmel, & Levkovitz, 2014; Elliott et al.,
1997; Linssen,Sambeth, Vuurman, & Riedel , 2012; Turner et al., 2003). Considering that
both planning and decision-making have been described to involve working memory,
impulse control and sustained attention (Lezak et al., 2012), and previous research has
demonstrated that prescription stimulants may result in small boosts in these areas of
cognition (Ilieva et al., 2015; Koelega, 1993; Riccio et al., 2001), it is possible that
prescription stimulants will also enhance planning and decision-making. Therefore, the
primary hypothesis of the present study is that among healthy adults without ADHD,
prescription stimulant medications will enhance performance on measures of processing
speed accuracy, planning time and accuracy, and advantageous decision-making, and
impair performance on measures of cognitive perseveration.
Methods
Literature search
The systematic search and retrieval process was conducted according to Lipsey
and Wilson’s (2001) guide for meta-analysis, the Preferred Reporting Items for
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Systematic Reviews and Meta-Analyses (PRISMA) 27-item checklist (Liberati et al.,
2009; Moher, Liberati, Tetzlaff, & Altman, 2009), and Okoli and Schabram’s (2010)
eight-step guide to systematic literature reviews. The study attempted to identify and
retrieve all empirical studies that examined amphetamine or methylphenidate effects on
processing speed, planning, decision-making and cognitive perseveration conducted at
any time. The final search and retrieval process was conducted in January 2016 and
included a comprehensive search of PsycINFO and PubMed. A combination of the
following keyterms were used: “Prescription stimulant”, amphetamine, Adderall,
methylphenidate, Ritalin, or Concerta, and “processing speed”, “psychomotor
performance”, planning, “decision making”, “cognitive flexibility”, “Digit Symbol
Substitution Task”, “Iowa Gambling Task”, “Spatial Planning Task”, “Set Shift
Task”, or “Wisconsin Card Sorting Task”. Studies were also searched within a larger
pilot study that investigated the effects of prescription stimulants and prostimulants on
multiple domains of cognition, as well as the following review articles: Advokat, (2010),
Linssen, Sambeth, Vuurman, and Riedel (2014), Smith and Farah, (2011), and Repantis,
Schlattmann, Laisney, and Heuser, (2010). Titles, abstracts, and full articles were
examined to assess if studies met eligibility criteria, described in the following section.
Study Selection
Studies were selected for review based on the following criteria:
A. The study investigated the effects of oral ingestion of amphetamine or
methylphenidate on processing speed accuracy, planning time, planning
accuracy, advantageous decision-making, or cognitive perseveration using the
Digit Symbol Substitution Test (DSST), the Iowa Gambling Task (IGT), the
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Tower of London (TOL) or New Tower of London (NTOL) Tasks, the
Wisconsin Card Sorting Task (WCST), or the Intra-Extra Dimensional Setshift Task (IDED); if the study investigated additional drugs or measures, only
data involving the stimulants listed previously and placebo were included.
B. The study was published in English.
C. The study used a double blind placebo-controlled design.
D. The sample included human subjects only, at least 18 years of age; if the study
included special groups, only data involving healthy controls were included.
E. The sample size was greater than one; single case studies were excluded.
F. The procedure did not limit sleep for participants; studies investigating sleep
deprivation or studies that deprived participants of sleep were excluded.
G. Studies that used drug discrimination learning procedures, i.e., teaching
participants to discriminate between drugs or doses of drugs, were excluded in
order to minimize confounds associated with these learning tasks.
Data extraction
Once all studies were identified and retrieved, data were extracted and coded
independently by two researchers according to a standardized coding manual. To measure
coder consistency, we calculated percent agreement (94.07%) based on established
guidelines (Lipsey & Wilson, 2001; Yeaton & Wortman, 1993) and disagreements were
resolved by discussion and consensus between coders. A comprehensive coding system
included basic descriptive statistics (sample size, reported effect size statistics, effect
direction and raw data to recalculate effect size), sample descriptors, study design and
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study, stimulant medication descriptors, dependent constructs and measures of cognition,
and the following moderators:
(1) Stimulant type (methylphenidate vs. amphetamine): Differences between
methylphenidate (MPH) and amphetamine (AMP) were examined to
determine if type of stimulant impacted cognitive neuroenhancement.
(2) Dose (low vs. high): We examined the influence of dose level on stimulants
for neurocognitive enhancement. Doses coded as “high” included the
following: ≥ 20-mg (AMP), ≥ 40-mg (MPH). “Low” doses were those that fell
below this convention. When studies reported dose in units of mg/kg, doses
were multiplied by the global average adult weight of 62-kg (Walpole et al.,
2012) and then coded accordingly. One study (Elliott et al., 1997) only
reported the collapsed findings from 20-mg (n = 8) and 40-mg (n = 20) of
MPH because the researchers did not find significant differences between the
doses. Considering the majority of participants received the highest dose, we
coded effect sizes as “high.”
(3) Sex Distribution: Percent female was coded as an estimate of sex distribution.
(4) Age of Sample: Mean age and age range were coded to determine the
influence of participant age on prescription stimulant neuroenhancement.
(5) Study Design (crossover vs. parallel): Studies were coded as using either a
crossover or within-subjects design or a parallel or between-subjects design.
(6) Inclusion of Non-Behavioral Measures (yes vs. no): For an additional
assessment of publication bias, we followed a format similar to Ilieva et al.
(2015) and differentiated studies that examined prescription stimulant effects
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on behavioral tasks only and studies that examined prescription stimulant
effects on behavioral tasks to better understand neurological or physiological
outcomes. Studies that conducted cognitive assessments in conjunction with
neurological (e.g., functional Magnetic Resonance Imaging [fMRI], Event
Related Potentials [ERP]) or physiological (e.g., electroencephalogram
[EEG], electrocardiogram [EKG]) assessments were coded in order to account
for any influence of non-behavioral measures. Studies that utilized biological
assessments (e.g., blood samples, saliva samples, blood pressure) were not
coded in this category.
(7) Timing of Dose Activation (during, prior, vs. after task): Timing of dose
activation was coded as occurring during learning processes, prior to learning
process, or after learning processes according to the medication type used in
each study. Studies utilizing pharmacokinetic data have indicated that plasma
levels peak after oral ingestion of short-acting amphetamine between 2-3
hours (Angrist, Corwin, Bartlett, & Cooper, 1987; Wachtel, ElSohly, Ross,
Ambre, & de Wit, 2002) and short-acting methylphenidate between 1-2 hours
(Kimko, Cross, & Abernethy, 1999; Volkow et al. 1998). Therefore, doses
administered within these time windows for each medication were coded as
occurring “during learning,” doses administered prior were coded as occurring
“prior to learning,” and doses administered following were coded as occurring
“after learning.”
Outcome performance measures and cognitive domains
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Dependent performance measures and constructs were coded based on methods
used by previous research and on theoretical constructs of cognition. In order to minimize
measurement error, an a priori outcome selection strategy similar to that used by previous
meta-analytic studies (Ilieva et al., 2015) was used whereby instruments and measures
were limited based on reliability and validity and commonality across studies (see Table
1). The present meta-analysis focused on studies addressing the effects of prescription
stimulants on the cognitive behaviors of processing speed accuracy, planning time,
planning accuracy, advantageous decision-making, and cognitive perseveration because
no meta-analyses have addressed these areas and because these areas proffer important
implications for prescription stimulant misuse for academic enhancement. Specific
instruments included: A) the Digit Symbol Substitution Task (DSST) to measure
processing speed accuracy, B) the Iowa Gambling Task (IGT) to measure advantageous
decision-making, C) the Tower of London Spatial Planning Task (TOL) and New Tower
of London Spatial Planning Task (NTOL) to measure planning accuracy and time, and C)
the Wisconsin Card Sorting Test (WCST) and the Intra-Extra Dimensional Set-shift Task
(IDED) to measure cognitive perseveration.
Processing Speed. Processing speed typically refers to the amount of time
required to make an accurate judgment of a stimulus (Cella & Wykes, 2013; Owsley,
2013). Completed with paper and pencil or on the computer, the Digit Symbol
Substitution Task (DSST) measures attention, motor performance, response speed and
visuomotor coordination (Silber, Croft, Papafotiou, & Stough, 2006) and on the Wechsler
Adult Intelligence Scale – Fourth Edition (WAIS-IV), the DSST score is combined with
the Symbol Search task score to generate a standard score of processing speed that
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measures skills in speed of mental problem-solving, attention, and hand-eye coordination.
The task provides a list of nine individually paired digits and symbols that participants
use as a key to substitute numbers with symbols as efficiently as possible (Litchenberger
& Kaufman, 2009). Although a number of additional measures of processing speed are
available in the literature (e.g., continuous performance tests, trail making tasks, and
reaction time), these tasks rely on a wide range of dimensions of performance. To
minimize heterogeneity in cognitive processes, and because the DSST is used widely in
the literature as a control measure of processing speed, accuracy measures of the DSST
were selected to measure processing speed. Accuracy measures included number of trials
correct in a specified amount of time (accuracy - total) or proportion of correct trials out
of total trials attempted in a specified amount of time (accuracy - proportion).
Planning and Decision-Making. Among other capacities, planning and decisionmaking require looking ahead, objective assessments, perceiving alternatives, weighing
choices, and utilizing conceptual frameworks (Lezak et al., 2012). Memory, impulse
control, and sustained attention are all necessary components of planning and decisionmaking behavior. Tests of planning may include gambling tasks and test of decisionmaking may include tower tests (Lezak et al., 2012).
Although a number of iterations of gambling tasks are available, a commonly
used task is the Iowa Gambling Task (IGT). The IGT is played with cards on a computer
in which the participant selects varying decks and cards with the purpose of minimizing
losses and winning as much money as possible (Lezak et al., 2012). The IGT presents
four decks of cards of which half yield consistent large gains and larger losses and half
yield consistent small gains and smaller losses (Agay et al., 2014). We prioritized number
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of advantageous choices or probability of selecting most likely outcomes from the IGT to
measure the tendency to choose advantageously within decision-making. Note that the
number of disadvantageous choices was equal to the total number of choices minus the
number of advantageous choices (i.e., when added together, they sum to the total number
of opportunities); therefore, the number of disadvantageous choices was also used as a
negative representation of advantageous choices.
The Tower of London Spatial Planning Task (TOL) and the New Tower of
London Spatial Planning Task (NTOL) are the most commonly used versions of the
tower tasks. These tasks require participants to rearrange rings or balls of varying colors
to arrive at the solution using the least number of moves and in the most direct way
(Lezak et al., 2012). The TOL requires participants to physically move the balls or discs
to come to the most efficient solution. The NTOL also requires participants to work out
the most efficient solution; however participants do not physically arrange the balls/discs
as they do in the TOL (Elliott et al., 1997). Both planning accuracy and planning time
were selected as measures of planning from the TOL and NTOL.
Cognitive Perseveration. Tasks of cognitive flexibility and the capacity to shift
require respondents to shift their thinking by changing the rules during the task (Lezak et
al., 2012). The Wisconsin Card Sorting Test (WCST) and the Intra-Extra Dimensional
Set-shift Task (IDED) are common tests of cognitive flexibility with performance
outcomes that measure cognitive perseveration (Lezak et al., 2012; Wild & Musser,
2014). The WCST is used to assess abstract concepts and set-shifting (Spreen & Strauss,
1998) by requiring participants to deduce a pattern by matching cards of varying symbols
and shapes based on the examiner’s cues (Lezak et al., 2012). An analog to the WCST,
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Cambridge Neuropsychological Test Automated Battery’s (CANTAB) IDED set shifting
test involves visual discrimination and attentional set formation (Barker, Pope, Smith,
Brown, & Hall, 2014; Wild & Musser, 2014). Participants view two color-filled shapes
and must learn through trial and error based on computer driven feedback which response
is correct (Cambridge Cognition, 2015). The test becomes increasingly difficult as it
progresses through nine stages, transitioning from intra-dimensional to extra-dimensional
rules (Wild & Musser, 2014). We focused on perseveration as a measure of flexibility,
prioritizing the selection of perseverative errors and Extra-dimensional reversal shift
errors from the WCST and IDED, respectively.
Statistical Methods
Meta-analyses, which pool weighted estimates of effects into a common metric
across studies (Aloe, 2014; Lipsey & Wilson, 2001), were conducted on the retrieved
studies using the program Biostat’s Comprehensive Meta-analysis (www.metaanalysis.com) (Borenstein, Hedges, Higgins, & Rothstein, 2015). In total, 15 individual
meta-analyses were conducted that included five measures of cognition across three types
of medication dose (averaged, low, and high medication doses). Because results were
similar across meta-analyses conducted separately for high and low doses only the
averaged medication dose findings are presented here (see Supplementary Tables S1a and
S1b). Primary analyses included effect size calculation for maximum change in cognition
of treatment compared to control. Additional analyses included visual inspection of
outliers, homogeneity tests of effect size distribution, analyses of publication bias, and
exploration of potential moderating variables.
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Assessment of Effect Size. Effect sizes measuring post-treatment differences
between placebo and control groups were calculated from a variety of statistics, including
descriptive data, i.e., means and standard deviations, and inferential statistics, i.e., F (in
cases of df = 1) and t. For missing raw data necessary for effect size computation, a
request for more information was made to researchers; otherwise, studies with missing
data for effect size computation were excluded. Effect sizes were combined from studies
that used both parallel and crossover designs. The appropriateness of synthesizing effect
size data across parallel and crossover designs has been largely debated in the
methodological literature (e.g., Elbourne et al., 2002; Lipsey & Wilson, 2001). Results
from studies using crossover designs may be biased from carryover effects where the
initial intervention effects may influence responses on subsequent interventions
(Elbourne et al., 2002). In order to identify heterogeneity between study designs, the
present study selected study design a priori as a moderator of interest.
Results were converted to the standardized mean difference (Hedge’s g) for
comparing across studies. The formulas for calculating Hedge’s g vary according to study
design and available data. In general, however, the formula for Hedge’s g is calculated by
taking d, which is the difference of group means divided by the pooled within group
standard deviation (Borenstein, Hedges, Higgins, & Rothstein, 2009; Hedges, 1981;
Lipsey & Wilson, 2001), then multiplying by the coefficient J, a correction factor to
account for small sample bias (Borenstein et al., 2009). Considering most of the included
studies used a within-subjects or crossover design, it is important to note that the
calculation of effect sizes from these studies require a different set of formulas than
between-subjects or parallel designs. While between-subjects studies’ natural unit of
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deviation is the standard deviation within groups, the standard deviation of the difference
score (SDDIFF) is the statistic of interest for estimating the natural unit of deviation for
within-subjects studies (Borenstein et al., 2009). The particular equations used to
calculate Hedge’s g for between-subjects or parallel designs and within-subjects or
crossover designs can be accessed in the Appendix (see Supplementary Tables S2a and
S2b).
Assumption of Independence. Meta-analysis relies on the assumption that each
measure of effect is representative of independent studies. Most studies investigating
prescription stimulant effects reported findings from multiple outcomes, however,
yielding a potential for multiple effect size estimates. Therefore, a protocol to handle
studies with more than one effect size was used and guidelines can be found in the
appendix (Supplementary Table S3).
Meta-analytic Technique. A random effects model, which assumes that
measured effect sizes are subject to sampling error and random effects variance (Lipsey
& Wilson, 2001), was chosen a priori given the heterogeneity of the design of studies
and cognitive measures as recommended by Field and Gillett (2010) and Hunter and
Schmidt (2000).
Homogeneity of the effect size distribution was tested visually, with forest plots,
and statistically, with the use of the Q statistic and I2 (95% CI) index. The Q statistic is a
standardized measure that approximates to a chi-square distribution with k – 1 degrees of
freedom, where k is the number of studies (Hedges & Olkin, 1984; Huedo-Medina,
Sánchez-Meca, Marín-Martínez, & Botella, 2006). A statistically significant Q is
indicative of a heterogeneous distribution, signaling the potential to test for moderators
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(Lipsey & Wilson, 2001). The I2 statistic is an index between 0 and 100% and is used as
an estimate for the amount of statistical impact of heterogeneity on the total observed
variation (Borenstein et al., 2009). Higgins, Thompson, Deeks, and Altman (2003) have
suggested heterogeneity can be interpreted as low (I2 = 25%), moderate (I2 = 50%), or
high (I2 = 75%).
In order to verify accurate data entry and to account for potential effects of
context within studies, a careful examination of any study level effect size outliers was
conducted. In the case where outliers were identified because of large sample sizes,
parallel analyses that included and excluded these outliers were conducted. To maintain
as much data as possible, only extreme outliers (falling more than 3 standard deviations
away from the mean) that were identified as irrelevant or out of context were removed
from the final analysis (see Supplementary Tables S4a, S4b, S4c, and S4d). Note that for
the present study, a decision to retain all studies in the subsequent analyses was made
considering their minimal effects on mean effect sizes.
While efforts were made to request descriptive and/or inferential data for every
eligible study that was missing the necessary data to calculate measures of effects, studies
in which data were not available for effect size calculations were excluded from the final
analysis. Case analysis for studies that did report moderator data was employed. A
decision to omit data, as opposed to imputing data, was made given the limited number of
studies examining prescription stimulant effects in the selected areas of cognition.
Finally, six different methods were used to assess level and presence of
publication bias: Egger’s regression index, the funnel plot, Duval and Tweedie’s trim and
fill, Rosenthal’s fail-safe N, Orwin’s adapted version of Rosenthal’s fail-safe N, and an
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assessment of publication bias (inclusion of non-behavioral measure) as a moderating
variable.
Statistical Tests of Moderators. Statistical tests of moderators were conducted
for variables identified a priori as described previously, as well as any of the additional
variables yielding a significant Q statistic. Because the moderating variables of interest
were both categorical (type of drug, ADHD status) and continuous (dose, timing of dose,
baseline functioning), analog to analysis of variance (ANOVA) and weighted regression
analysis (meta-regression) using mixed effects models were run for tests of moderators.
Results
Search results
A total of 1,296 titles were initially identified via the bibliographic databases
PsycINFO (257) and Pubmed (1039), including journal articles and book chapters (1273)
and dissertations (23). A total of 21 studies met eligibility criteria of which 16 studies had
sufficient data to calculate effect sizes met and were included in this study (see Table 2).
Of these, 8 studies with a total of 345 participants examined prescription stimulant effects
on processing speed, 5 studies with a total of 152 participants examined prescription
stimulant effects on planning and decision-making, and 6 studies with a total of 337
participants examined cognitive perseveration. A total of 10 studies examined the effects
of AMP and 6 studies examined the effects of MPH. Note that while eligibility criteria
allowed for both short-acting and long-acting agents, all of the included studies examined
short-acting agents.
Stimulant effects on processing speed accuracy
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Data were extracted from 8 studies that investigated the neurocognitive effects of
prescription stimulant medication on processing speed using a crossover design, resulting
in a total of 345 participants (see Figure 1). When all doses were averaged together,
under the random effects model, the studies generated a statistically significant mean
effect size of g =0.282 (95% CI 0.077, 0.488, p = .007), with effect sizes ranging between
g = −0.061 to g = 0.645. The heterogeneity of variance analysis was significant, Q (7) =
73.276 [I2 = 90.447], p <.001, indicating significant between-study variance.
Analysis of publication bias indicated minimal risk with a Rosenthal’s N of 218 to
lead to a p-value at or above an alpha of .05 and an Orwin’s N of 22 to reduce the
measure of effect to 0.10. Under the random effects model, trim and fill analysis
suggested the imputation of 4 studies to reduce negative bias resulting in an increased
effect size of g = 0.518 (95% CI 0.310, 0.726) (see Supplementary Figure 1) and Egger’s
regression was significant [B = −5.305, SE = 1.918, t(6) = 2.766, 95% CI −9.998, 0.612,
p = .032]. Five studies were excluded from the analysis because they did not have
sufficient data to calculate effect sizes. Findings from these studies were mixed; three
studies reported null findings (Crabbe et al., 1983; Holdstock & de Wit, 2001; Kennedy,
Odenheimer, Baltzley, Dunlap, & Wood, 1990), one study reported positive findings
(Hamidovic, Dlugos, Palmer, & de Wit, 2010), and the final study reported negative
findings (i.e., MPH was associated with a reduction in processing speed accuracy;
Kollins, Rush, Pazzaglia, & Ali, 1998). These findings suggest minimal risk of positive
publication bias within analyses examining processing speed.
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The significant Q statistic indicated between study variance so moderator analyses
were conducted. None of the moderators demonstrated significant differences through
metaregression or ANOVA analog.
Stimulant effects on planning time, planning accuracy, and advantageous decisionmaking
Stimulant effects on tendency to choose advantageously. Data were extracted
from 2 studies that investigated the neurocognitive effects of prescription stimulant
medication on tendency to choose advantageously, resulting in a total of 44 participants
(see Figure 2). When all doses were averaged together, under the random effects model,
the studies generated a mean effect size of g = −0.191 (95% CI −0.561, 0.180, p = .313).
The heterogeneity of variance analysis was not significant, Q (1) = 0.204 [I2 = 0.000], p
=.656, indicating minimal between-study variance. ANOVA analog did not reveal
significant differences between the study using a parallel design (g = -.045; Agay et al.,
2010) and the study using a crossover design (g = -0.241; Agay et al., 2014), Q(1) =
0.204, p = .652. Given the effect size for tendency to choose advantageously was not
statistically significant and the small number of studies included in the analysis, analysis
of publication bias and moderator analyses were not conducted.
Stimulant effects on planning accuracy. Data were extracted from 2 studies that
investigated the neurocognitive effects of prescription stimulant medication on planning
accuracy, resulting in a total of 79 participants (see Figure 3). When all doses were
averaged together, under the random effects model, the studies generated a mean effect
size of g =0.048 (95% CI -0.194, 0.290), p = .698) that was not statistically significant,
with effect sizes ranging from g = 0.024 to g = 0.146. The heterogeneity of variance
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analysis was not significant, Q (1) = 0.150 [I2 = 0.000], p =.698, indicating minimal
between-study variance. ANOVA analog did not reveal significant differences between
effect sizes from the study using a parallel design (g = 0.146; Turner et al., 2003) and the
study using a crossover design (g = 0.024; Linssen et al., 2012), Q(1) = 0.150, p = .698.
Publication bias and further moderator analyses were not conducted due to the small
number of studies and minimal between-study variance.
Stimulant effects on planning time. Data were extracted from 3 studies that
investigated the neurocognitive effects of prescription stimulant medication on planning
time, resulting in a total of 107 participants (see Figure 4). When all doses were averaged
together, under the random effects model, the studies generated a mean effect size of g =
−0.140 (95% CI −0.383, 0.102, p = .257) that was not statistically significant, with effect
sizes ranging from g = -0.561 to g = 0.006. The heterogeneity of variance analysis was
not significant, Q (2) = 3.452 [I2 = 42.062], p =.178.
Given the effect size for planning time was not statistically significant, analysis of
publication bias with Rosenthal’s N and Orwin’s N was not conducted. Trim and fill
analysis indicated the imputation of 2 studies to reduce negative bias resulting in an
effect size approaching 0, g = 0.006 (95% CI −0.237, 0.248) (see Supplementary Figure
2). Egger’s regression was not significant [B = -3.386, SE = 1.020, t(1) = 3.319, 95% CI
−16.350, 9.578, p = .186]. These findings suggest minimal risk of publication bias within
analyses examining planning and decision time. ANOVA analog examining differences
between effect sizes from the study using a parallel design (g = -0.561; Turner et al.,
2003) and the two studies using a crossover design (g = -0.060; Elliott et al., 1997;
Linssen et al., 2012) was not significant, Q(1) = 2.808, p = .094. Given the small number
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of studies available for analyses and the minimal heterogeneity between studies,
additional moderator analyses were not conducted.
Stimulant effects on cognitive perseveration
Data were extracted from 6 studies that investigated the neurocognitive effects of
prescription stimulants on perseveration, resulting in a total of 337 participants (see
Figure 5). When all doses were averaged together, under the random effects model, the
studies generated a mean effect size of g =0.003 (95% CI −0.095, 0.101), p = .949) that
was not statistically significant, with effect sizes ranging from g = −0.138 to g = 0.254.
The heterogeneity of variance analysis was not significant, Q (5) = 2.866 [I2 = 0], p =
.721.
Given the effect size for cognitive perseveration was not statistically significant,
analysis of publication bias with Rosenthal’s N and Orwin’s N was not conducted. Trim
and fill analysis indicated the imputation of 3 studies to reduce negative bias resulting in
a negative effect size of g = −0.021 (95% CI −0.114, 0.072) (see Supplementary Figure
3). Egger’s regression was not significant [B = 0.684, SE = 0.495, t(4) = 1.381, 95% CI
−0.691, 2.060, p = .239]. These findings suggest minimal risk of publication bias within
analyses examining cognitive perseveration. ANOVA analog did not reveal significant
differences between effect sizes based on study design, Q(1) = 1.206, p = .272, in which
two studies used a parallel design (g = 0.236) and four studies used a crossover design (g
= -0.010). The overall Q statistic was not significant, indicating minimal between study
variance so additional moderator analyses were not conducted.
Discussion
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The primary indications for ADHD prescription stimulant medication (e.g.,
Adderall, Ritalin, Dexedrine) are for the reduction of ADHD symptoms including
impulsivity, hyperactivity, inattention. A, n increasing number of college students and
non-student adults with and without ADHD, however, have reported misusing these
medications to enhance their academic functioning or productivity. Previous research
examining the effects of prescription stimulant medication on cognition has typically
relied on small sample sizes and yielded mixed results. Therefore, the present study
conducted 15 meta-analyses to explore the potential for prescription stimulant medication
as a neurocognitive enhancer, as well as influencing factors associated with its
neurocognitive effects.
Consistent with our primary hypothesis, prescription stimulant medication
showed consistent and positive effects for increasing processing accuracy (g = 0.282).
Study results for processing speed did not differ by dose level or across samples of
varying ages or gender distributions. This finding is consistent with previous metaanalytic study findings that these medications have small and significant effects on other
abilities of focused attention. Specifically, benefits from prescription stimulants in the
areas of working memory (g = 0.13), inhibitory control (g = 0.20) (Illieva et al., 2015),
and measures of vigilance (Riccio et al.,2001) have been reported in the literature.
Previous researchers have questioned if prescription stimulants are associated
with impairments of other components of cognition such as cognitive flexibility or
perseveration (Advokat, 2010; Smith & Farah, 2011; Weyandt et al., 2013). Contrary to
our hypothesis, the present study did not support the association of prescription
stimulants with impairments in the area of cognitive perseveration (g = 0.003). Results
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also revealed non-significant effects for tendency to choose advantageously (g = −0.191),
planning accuracy (g = 0.048), and planning time (g = −0.140). It is important to note,
however, that the small number of studies investigating these outcomes limit the
interpretation of these findings. Indeed, the analysis examining the effects of MPH relied
on a combined sample size of n = 44 among only 2 studies and resulted in a small
negative effect size. One of these studies (Agay, 2014) also reported that participants
with low performance at baseline tended to improve and those with high performance
tended to demonstrate impairments. Unfortunately, due to the limited number of studies
examining the effects of prescription stimulants on planning time, planning accuracy, and
advantageous decision-making, analyses exploring moderator variables were not
conducted in the present study. Thus, adequately powered studies that also take into
accounts individual differences are needed to fully understand if prescription stimulants
truly cause impairments to decision-making.
Implications
Even with findings supporting significant effects of prescription stimulant
medication on processing speed accuracy, the question remains as to how meaningful
these effects are in settings outside of the laboratory. In particular, are these effects
meaningful for college students engaging in illicit stimulant misuse for academic
purposes and non-student adults misusing stimulants for productivity? The included
studies conducted cognitive assessments in research laboratories, providing an
environment quite unlike one in which college students and other adults would normally
work, study, read or write. In fact, research accumulated over the past three decades has
suggested prescription stimulant medication results in minimal to no effects on the
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overall academic achievement in children with ADHD, even though it may increase
attention and improve productivity, (Advokat, 2010; Lakhan & Kirchgessner, 2012).
Studies that directly investigate the neurocognitive effects of prescription stimulant
medication on academic tasks and work productivity will help shed light on how
meaningful the effects found in the present study are regarding prescription stimulant
misuse.
Another important consideration is the wide range of medication doses included
in the present study that may not reflect the levels of medication college students and
other adults are misusing. The literature on prescription stimulant misuse does not
provide an indication of the typical dose being misused; however, medication is most
effective when titrated according to individual assessment (Coghill et al., 2013) and some
individuals appear to perform better with lower doses compared to higher ones. If varying
doses also result in cognitive impairments (or worse, adverse health outcomes), college
students and other adults would benefit from safety information and efficacy information
regarding prescription stimulant medication dose. Future studies investigating
prescription stimulant effects on tasks involving actual academic assignments (e.g., essay
composition, calculus problems) or work productivity, comparing doses optimal for
behavior improvement to lower doses in adult populations would shed light on this issue
(Weyandt et al, 2013; Weyandt et al., 2014).
Of note, there are a number of interventions being explored for their potential as
cognitive neuroenhancers for processing speed that could serve as an alternative to
prescription stimulant medication, including video games (between d = 0.48 to d = 1.47;
Dye, Green, & Bavelier, 2009), and exercise (d = 0.091;Chang, Labban, Gapin, & Etnier,
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2012). Although the present study’s findings revealed smaller effect sizes from
prescription stimulant medication for processing speed enhancement than the previously
described video game interventions, the ease of taking a medication compared to longterm trainings and programs should not be overlooked. Even a small boost in
enhancement may be meaningful when applied to an increase in a grade for college
students (Ilieva et al., 2015), especially considering it can result in near immediate
effects.
Methodological Considerations
The present study has a number of strengths that support its contribution towards
uncovering the potential of prescription stimulant medication as a neurocognitive
enhancer. Studies were searched for and retrieved from multiple bibliographic databases
in order to capture as much data as possible and minimize publication bias. This study
was the first meta-analysis to explore the effects of prescription stimulant medication on
cognitive perseveration, planning and decision-making. Importantly, a major strength of
the present study involved the well-established methodology applied to calculate mean
effect sizes and test for moderator variables. It is particularly important to emphasize that
previous studies examining the neurocognitive effects of prescription stimulant
medication have relied on sample sizes that were likely underpowered. Indeed, the 16
studies included in the present study relied on small sample sizes (mean n = 35) and
resulted in small effect sizes. Therefore, this meta-analytic study, which pooled weighted
estimates of effects and resulted in more power than individual studies, contributes
substantially to the literature.
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A number of limitations are also important to note, however, relating to the
study’s design and methodology and studies investigating the cognitive effects of
prescription stimulant medication in general. First, a limitation concerning meta-analysis
methodology concerns its potential to overlook important individual variation by
focusing on between-study variance (Egger & Smith, 1998). For example, the inclusion
of one study (Turner et al., 2003) that focused on healthy elderly males may represent
findings relevant only to elderly populations and limits the generalizability of this study.
Additionally, meta-analysis is plagued by issues of limited power for moderator variable
detection (Hedges & Pigott, 2004). The absence of significant moderator variables in the
present study may reflect a lack of power as opposed to lack of variability.
A related issue that is often raised regarding meta-analyses is the potential
influence of publication bias on meta-analytic findings. Because methods to measure and
minimize publication bias may require a larger number of studies than included in the
present study, we utilized a wide range of techniques (Egger’s regression index, the
funnel plot, Duval and Tweedie’s trim and fill, Orwin’s adapted version of Rosenthal’s
fail-safe N, and an assessment of publication bias as a moderating variable) to account for
this limitation. Findings from publication bias analyses suggested that in general the
included studies tended towards negative bias. In other words, the present study may
have overrepresented smaller and more negative effects in the literature as opposed to
larger and positive effects, which are typically associated with publication bias. Still, a
concern regarding the exclusion of missing data should be noted.
Previous meta-analyses examining the efficacy of prescription stimulant
medication for improvements in ADHD symptoms have found significant differences
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between studies using change scores, i.e. studies comparing baseline scores, and posttreatment (or endpoint scores), i.e. studies comparing changes between placebo and
medication scores, as measurement outcome (Faraone et al., 2006). Because all of the
studies included in the present study reported data to calculate endpoint scores, findings
in the present study were based on differences between placebo and medication scores.
Another important consideration is the susceptibility of meta-analysis to overlook
important influences, such as the social context of the study, the quality of the study, and
theoretical influences/implications (Lispey & Wilson, 2001). For example, in their metaanalysis assessing stimulant effects on ADHD symptomatology, Faraone & Glatt (2010)
suggested that the systematic variability across methodology between classes of drugs
may have produced misleading results. On the other hand, two recent reviews exploring
the cognitive effects of prescription stimulant medication in children (Pietrzak, Mollica,
Maruff, & Snyder, 2006) and in adults (Linssen et al., 2014) suggested that the use of
meta-analysis for these investigations would be inappropriate due to the variability across
study methodology, participant characteristics, treatment conditions and
neuropsychological instruments used across studies. In order to account for variability,
the present study only included studies meeting more rigid criteria (e.g., specific
measures only).
Finally, although meta-analysis is a powerful method that may help uncover the
true effect of an intervention (Kraemer, Gardner, Brooks, & Yesavage, 1998), results are
limited by the quality of available published studies. Many criticisms of meta-analysis
stem from the decision to either maintain open inclusion criteria (leading to a variety of
studies that may not be comparable) or to adopt rigid inclusion criteria (resulting in less
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meaningful findings because of the exclusion of potentially meaningful studies) (Kraemer
et al., 1998). Although the present study used specific inclusion criteria to select studies
meeting standards of quality, a wide variety of study designs and study methodology
were included. It is important to note that study design was selected a priori as a
moderator variable and differences in effect sizes across parallel and crossover studies
were not found; however, the small number of included studies also limited these
analyses.
Finally, a critically important limitation in this literature was the omission of
reporting participant ethnicity across most studies. It is unclear why so few studies
investigating the cognitive effects of prescription stimulant medication reported
participant ethnicity, but it will be important for future research to include more
ethnically diverse populations.
Future Research
The present findings suggest that prescription stimulant medication may act as a
neurocognitive enhancer of processing speed without impeding other domains of
cognition such as flexibility. These effects, although small, appear to be significant for
adults of varying ages and may be comparable for men and women. Still, a number of
questions remain unanswered about the effects of prescription stimulant medication for
cognition among varying populations that may help elucidate their mechanism of action.
Research is warranted to further investigate a number of areas related to
prescription stimulant medication for cognitive enhancement. The potential for
moderating effects of participant characteristics, particularly baseline cognitive
functioning and related genotype variability, need to be clarified. If only adults with
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lower baseline cognitive functioning scores or those homozygous to a particular genotype
receive neurocognitive benefits from prescription stimulants many adults misusing
prescription stimulants are taking unnecessary risks with minimal results. Or worse, if
prescription stimulant medication actually impairs cognitive functioning in certain
individuals, some adults may actually be worsening their ability to engage in higher-level
learning.
Although the present study’s findings are clinically and empirically important,
limitations related to the external validity of the included measures limit the finding’s
generalizability to populations in academic settings. More specifically, research
examining representative populations of college students will directly inform the
potential enhancement or impairments associated with prescription stimulant misuse
during late adolescence and early adulthood. Considering the neurodevelopmental
changes that occur during late adolescence and early adulthood, findings from the present
study that included adults across a range of ages may not adequately represent the manner
in which prescription stimulant misuse impacts cognition in college aged populations.
The present study addressed cognitive constructs not previously studied, but
additional areas of cognition should also be investigated in relation to prescription
stimulant medication. For example, prescription stimulant medication may offer greater
benefits for other areas of cognition, such as volition and motivation, the latter of which
has been suggested to be a mechanism of prescription stimulants for neuroenhancement
(Volkow et al., 2008). Additional measures of processing speed (e.g., continuous
performance tasks, response time for item recognition tasks) should also be examined to
validate the present study’s findings that prescription stimulants may proffer benefits for
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processing speed accuracy. Furthermore, the finding that prescription stimulant
medication did not result in effect sizes significantly different than zero on tasks of
planning time and accuracy, advantageous decision-making, and cognitive perseveration
was based on a small number of studies, requiring further examination.
Finally, further research is warranted to better understand the underlying
statistical power of studies that have examined the effects of prescription stimulant
medication on neurocognitive enhancement. Sample sizes of the studies included in the
present investigation ranged from n = 6 to n = 192; however, the vast majority of studies
(k = 11, 68.75%) relied on sample sizes that included less than 30 participants.
Considering the consistently small effect sizes found in the present study, it is likely that
these and previous studies examining cognition and prescription stimulant medication
have been greatly underpowered. Given this serious limitation in the literature, future
studies should reference findings from existing meta-analyses as guides when
determining required sample sizes.
Future Directions
A number of ethical and social issues related to prescription stimulant medication
as a neurocognitive enhancer have garnered attention in the literature (e.g., Dubljević,
2013; Farah, 2004; Goodman, 2010). Critics of cognitive neuroenhancers have compared
cognitive neuroenhancement to cheating, arguing that gains made under
neuroenhancement cannot be claimed as the user’s own (Goodman, 2010). However, a
recent survey of German students revealed only small correlations between the use of
cognitive neuroenhancers and the acts of plagiarism and fabrication (Dubljević, Sattler, &
Racine, 2014), suggesting users may not necessarily perceive cognitive
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neuroenhancement to be as unethical as acts generally considered to be cheating.
Arguments about the equivalence of cognitive neuroenhancement to academic dishonesty
are analogous to debates about the use of anabolic steroids and human growth hormone
performance among professional athletes – that are now generally considered to be illegal
in most professional sports leagues. Yet, pharmacological enhancement is not unique to
the area of cognition as it is already being used to control mood, sleep, appetite and sex
(Farah, 2004; Farah et al., 2004).
The present study’s findings, in conjunction with previous research, indicate that
prescription stimulant medication provides small, but significant cognitive effects across
multiple domains of cognition, i.e., cognitive neuroenhancement. Irrespective of peoples'
ethical and professional views on the issue, prescription stimulants are being used
illegally for the purpose of cognitive neuroenhancement and at high rates across many
college campuses. Therefore, the establishment of public policies surrounding this issue,
whether restrictive or liberal, is of critical importance. An important policy consideration
concerns the abuse potential of prescription stimulants among healthy college students
and non-student adults. Evidence supports that both AMP and MPH hold a high abuse
potential for physiological and/or psychological dependence, but instances of abuse
among ADHD populations are actually rare (Kollins, 2007). To date, the literature on
prescription stimulant misuse has largely focused on prevalence rates and adult
characteristics associated with misuse. Research examining the potential for
psychological and physical abuse of these drugs among healthy adults is sorely needed to
inform the development of public policy concerning this issue. As Farah and colleagues
(2004) aptly explained, “The question is therefore not whether we need policies to govern
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neurocognitive enhancement, but rather what kind of policies we need” (p. 424). The
answer to this question needs to be informed by collaborative efforts across the sciences.
The interdisciplinary nature of this public policy issue is clear, as cognitive effects and
potential for abuse from prescription stimulants likely depend on the interplay of
individual characteristics (i.e., genetic variability), pharmacological mechanisms and
actions, and cognitive effects encompassing behavioral science and behavioral
neuroscience.
Conclusion
The present study supports the effectiveness of prescription stimulant medication
for neurocognitive enhancement of processing speed accuracy in the adult population.
While preliminary findings also indicate prescription stimulant medication does not
appear to impair nor enhance planning, decision-making or cognitive perseveration, it is
important to note that only a small number of studies addressed these outcomes. The
present findings suggest that college students misusing prescription stimulants for
academics and non-student adults misusing prescription stimulants for productivity may
actually receive meaningful benefits. Further research is warranted, however, to
investigate whether enhancement of tasks of cognition translate to boosts in academic
grades in the college setting or increased productivity in the workplace. Public policy
informed by collaborations across the sciences that addresses the use of prescription
stimulant medication for neurocognitive enhancement is needed given the
interdisciplinary nature of this topic.
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Figure Legends
Figure 1. Overview of meta-analysis of processing speed accuracy. Eight studies
examining effects of amphetamine on processing speed accuracy; Summary Cohen’s d
calculated with random effects model.
Figure 2. Overview of meta-analysis of tendency to choose advantageously. Two studies
examining effects of methylphenidate effects on tendency to choose advantageously;
Summary Cohen’s d calculated with random effects model.
Figure 3. Overview of meta-analysis of planning accuracy. Two studies examining
effects of methylphenidate effects on planning accuracy; Summary Cohen’s d calculated
with random effects model.
Figure 4. Overview of meta-analysis of planning time. Two studies examining effects of
methylphenidate effects on planning time; Summary Cohen’s d calculated with random
effects model; RT = response time.
Figure 5. Overview of meta-analysis of cognitive perseveration. Six studies examining
effects of amphetamine and methylphenidate effects on cognitive perseveration;
Summary Cohen’s d calculated with random effects model; ED = Extra dimensional.

